Goldman Sachs
EVMN

Goldman Sachs’s Evommune Inc EVMN Stock Holding History

Goldman Sachs’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Buy
154,323
+92,648
+150% +$2.09M ﹤0.01% 4019
2025
Q4 		$1.06M Buy
+61,675
New +$1.16M ﹤0.01% 5099

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs's EVMN Position: Q1 2026 in Review

Goldman Sachs increased its Evommune Inc (EVMN) stake by 150% in Q1 2026, buying an estimated $2.09M and bringing the position to 154,323 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4019.

Goldman Sachs first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Goldman Sachs held 154,323 shares of Evommune Inc worth $3.55M as of Q1 2026.
  • Goldman Sachs bought 92,648 Evommune Inc shares in Q1 2026, an estimated $2.09M.
  • Evommune Inc made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4019 holding.
  • Goldman Sachs first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.